US News and World Report and Pharmacy Times Survey: Advil®, Centrum® and Robitussin® are #1 Pharmaci
US News and World Reportand Pharmacy Times Survey: Advil®, Centrum® and Robitussin® are #1 Pharmacist Recommended
Many Pfizer Consumer Healthcare Products Receive Prestigious Ranking
MADISON, N.J.--(BUSINESS WIRE)-- - U.S. News & World Report and Pharmacy Times, this week, published rankings of the Top Recommended Health Products, and Pfizer Consumer Healthcare (PCH) received top honors based on a recent survey of pharmacists across the U.S. The survey rankings showed Advil®, Centrum® and Robitussin® as the number one pharmacist recommended in each of their respective categories.
"At Pfizer Consumer Healthcare, we create safe and highly effective healthcare solutions designed to improve consumers' lives," said Brian Groves, Chief Marketing Officer at Pfizer Consumer Healthcare. "Pharmacists across the country play a critical role in providing healthcare counsel to consumers. To be recognized by this important group is an honor and proof that our commitment to quality and efficacy is our top priority when we develop and maintain our products."
Advil®, which just kicked off its Advil® Relief in Action campaign that honors and supports volunteers, has been helping relieve pain for more than 25 years. Millions of people trust Advil® for unsurpassed relief of their aches and pains and PCH is proud to be recognized as #1 in the Oral Anti-Inflammatory category.
As the most-studied, most-recommended and most-preferred multivitamin brand in America, PCH is also pleased that Centrum® ranked #1 in the Multivitamins category, backed by over 30 years of nutritional expertise and science.
Robitussin® has reliably treated cough, cold and flu symptoms through a variety of different formulations tailored to fit different symptom combinations. The Robitussin® portfolio was recognized in five categories by U.S. News & World Report and Pharmacy Times, including the #1 ranking in the Cough/Cold/Flu Combinations - Liquid Formulations category.
Other Notable Pfizer Consumer Healthcare Product Rankings:
ThermaCare®ranked first in the Thermal Relief Products category
Advil® Cold and Sinusranked first in the Cough/Cold/Flu Combinations - Daytime category
Preparation H® ranked first in the Hemorrhoidal Preparations category
Emergen-C® ranked second in the Immune Support category
Advil® ranked second in the Oral Arthritis Pain Relievers category
Caltrate® ranked second in the Calcium Supplements category
Chapstick® ranked third in the Lip Balm category
Pfizer Inc.: Working together for a healthier world™
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com.
KEYWORDS: United States North America New Jersey
The article US News and World Report and Pharmacy Times Survey: Advil®, Centrum® and Robitussin® are #1 Pharmacist Recommended originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.